The limited clinical utility of a routine creatine kinase (CK) on admission to a psychiatric inpatient unit
Fraser A. M. Scott, Matt Butler, Jonathan P. Rogers · 2024
Read The limited clinical utility of a routine creatine kinase (CK) on admission to a psychiatric inpatient unit by Fraser A. M. Scott, Matt Butler, Jonathan P. Rogers (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11654146.txt.
Description
Many psychiatric wards run a blood test for creatine kinase on everyone admitted, hunting for a rare but deadly drug reaction. Fraser Scott, Matt Butler, and Jonathan Rogers check whether that routine pays off in this 2024 study of a South London mental health trust. The test can support diagnosis of neuroleptic malignant syndrome, a reaction to antipsychotic drugs that can kill.
Over four years and more than fourteen thousand admissions, about one in six patients got the test within two days of arrival. Roughly one in seven of those results ran at least four times the normal limit, a level that might suggest the syndrome. The team read the case notes for those high results to see whether the test changed any diagnosis or treatment. Their title gives the verdict: the routine test's clinical utility is limited.
Catalog record
| CREATOR | Fraser A. M. Scott, Matt Butler, Jonathan P. Rogers |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |